SCHEMBL16707188

SCHEMBL16707188

[2H]C([2H])([2H])c1cc(C)cc(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
ACHE P22303 3/20 0.44
CYP3A4 P08684 3/20 0.41
TSHR P16473 3/20 0.39
MAPK1 P28482 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
PTPN1 P18031 2/20 0.39
CYP1A1 P04798 2/20 0.37
CYP1B1 Q16678 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
ELANE P08246 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294715 0.95 ALDH1A1 (0.53) ALDH1A1ACHECYP3A4MAPK1TDP1
SCHEMBL145855 0.87 ALDH1A1 (0.62) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL29587173 0.84 ALDH1A1 (0.59) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL12501 0.81 ALDH1A1 (0.73) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL16116743 0.79 ALDH1A1 (0.42) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL4342018 0.77 ALDH1A1 (0.50) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL879948 0.75 ALDH1A1 (0.60) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL388060 0.75 ALDH1A1 (0.48) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL29427076 0.75 ALDH1A1 (0.48) ALDH1A1ACHECYP3A4TSHRMAPK1
SCHEMBL2952197 0.74 ALDH1A1 (0.53) ALDH1A1ACHECYP3A4PTPN1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9770432-B2 Deuterated benzopyran compounds and the use in the treatment of pain and inflammation GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2017-09-26 US disclosed
US-9763914-B2 Deuterated benzopyran compounds and application thereof GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2017-09-19 US disclosed
US-9676719-B2 Phenyl derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2017-06-13 US disclosed
US-20170020843-A1 DEUTERATED BENZOPYRAN COMPOUNDS AND APPLICATION THEREOF INFLAMAX PHARMACEUTICALS LIMITED (CN) 2017-01-26 US disclosed
US-20160287556-A1 DEUTERATED BENZOPYRAN COMPOUNDS AND APPLICATION THEREOF INFLAMAX PHARMACEUTICALS LIMITED (CN) 2016-10-06 US disclosed
US-9371305-B2 Deuterated benzopyran compounds and application thereof GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-06-21 US disclosed
US-20150133538-A1 Deuterated Benzopyran Compounds and Application Thereof GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133538-A1 Deuterated Benzopyran Compounds and Application Thereof PTGS2, HPGDS, PTGS1 ALDH1A1 324/4885ACHE 2101/4885CYP3A4 129/4885
US-20160287556-A1 DEUTERATED BENZOPYRAN COMPOUNDS AND APPLICATION THEREOF PTGS2, HPGDS, PTGS1 ALDH1A1 324/4885ACHE 2101/4885CYP3A4 129/4885
US-20170020843-A1 DEUTERATED BENZOPYRAN COMPOUNDS AND APPLICATION THEREOF PTGS2, HPGDS, PTGS1 ALDH1A1 324/4885ACHE 2101/4885CYP3A4 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.